Jinrui Jiye Joins 2026 Innovative Cancer Therapy Frontier Forum

Recently, the 2026 Frontier Forum on Innovative Cancer Treatments was successfully held in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan. The forum, themed "Intelligent Integration in Lecheng: Building a New Ecosystem for Cancer Treatment," brought together academicians and experts from both domestic and international arenas, clinical authority scholars, research institutions, and elites from the biopharmaceutical industry. The focus was on cutting-edge areas such as cell therapy, oncolytic viruses, homeostasis medicine, and precision diagnosis and treatment of central nervous system tumors. Leveraging the “licensed entry and pilot testing” policy advantages of Lecheng, participants explored new paths for innovative cancer technologies, clinical translation, and synergistic industrial ecosystem development. Lai Xintian, the chairman of Jinrui Bioindustry, attended the forum and deeply engaged in academic discussions and industry exchanges, actively integrating into the national collaborative development landscape for innovative cancer treatment.

Jinrui Jiye Chairman Lai Xintian onsite for the forum

The forum featured a stellar lineup of experts and a rich academic atmosphere, with renowned academicians from the Chinese Academy of Sciences such as Wei Yuquan and Shang Yongfeng attending the opening ceremony and delivering speeches. Among them, Wei Yuquan, an academician of the Chinese Academy of Sciences, the head of the National Key Laboratory of Biotherapy at Sichuan University, and the tumor center at West China Hospital, delivered a keynote report titled "Advances in Biopharmaceuticals and Biotherapy Research." He systematically reviewed the transition of biopharmaceuticals from laboratory research to clinical application in recent years, analyzing the latest breakthroughs and future trends in cutting-edge biotherapy technologies such as antibody drugs, cell therapy, and oncolytic viruses. He pointed out that biotherapy has become the fourth pillar of cancer treatment following surgery, radiation therapy, and chemotherapy, laying a solid theoretical foundation for innovative cancer treatments and indicating future research directions.

Academician Yuquan Wei of the Chinese Academy of Sciences, affiliated with the State Key Laboratory of Biotherapy (Sichuan University) and Cancer Center of West China Hospital; Chairman of the Company’s Scientific Advisory Board and core inventor of JRF101 patents.

Professor Wenbin Li from Beijing Tiantan Hospital, Capital Medical University, the Company’s core clinical collaboration expert, unveiled Phase II clinical trial data of JRF101 for recurrent glioblastoma at the forum.

Glioblastoma is the most aggressive type of brain malignancy. Patients with recurrent disease face limited therapeutic options and dismal prognosis, leaving substantial unmet medical needs. The released Phase II results demonstrate that the novel agent JRF101 features favorable safety profiles and potent anti-tumor efficacy, opening a groundbreaking therapeutic avenue for recurrent glioblastoma and laying a solid foundation for subsequent clinical development.

Independently developed by Jinrui Jiye, JRF101 is a small-molecule liposomal drug targeting the tumor microenvironment. It modulates the tumor microenvironment via multiple pathways to rectify abnormalities in tumor immunity, metabolism and angiogenesis, thereby restraining malignant tumor progression. As the Company’s flagship pipeline candidate built on its proprietary liposome technology platform, JRF101 is advancing steadily through clinical trials and is expected to deliver new therapeutic hope for patients with brain tumors.

Professor Wenbin Li from Beijing Tiantan Hospital, Capital Medical University (Core Clinical Cooperation Expert of our company)

As a high-tech enterprise specializing in innovative anti-cancer drug R&D, Jinrui Jiye has long-standing partnerships with top-tier domestic research institutes and Grade A tertiary hospitals including the State Key Laboratory of Biotherapy at Sichuan University, West China Hospital of Sichuan University and Beijing Tiantan Hospital. The company has built a full-spectrum innovation ecosystem covering drug discovery, clinical development and industrial translation. Leveraging its core strengths in natural-product-based anti-tumor research and liposomal nanocarrier delivery technology, Jinrui Jiye keeps advancing its pipeline focusing on severe solid tumors such as brain malignancies and non-small cell lung cancer, with multiple candidate drugs progressing smoothly through clinical stages.

During the forum, Jinrui Jiye held in-depth exchanges with academicians, leading clinicians and industrial counterparts. These communications strengthened existing academic ties and expanded pathways for industrial collaboration. Going forward, adhering to an innovation-driven development strategy, the company will capitalize on favorable policies of Boao Lecheng International Medical Tourism Pilot Zone and academic resources to accelerate the clinical translation of core assets including JRF101. By deepening integrated industry-university-research-medical innovation, Jinrui Jiye will keep developing proprietary China-originated innovative medicines with independent intellectual property rights and high clinical value. The company aims to improve the innovative cancer treatment landscape and deliver safer, more accessible therapeutic options for cancer patients worldwide.